1-3 of 3
Xiaoling Xuei
Close
Sort by
Journal Articles

Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: A Report from the Children's Oncology Group

Elliot Stieglitz, Alex Lee, Steven P. Angus, Christopher Davis, Donald Barkauskas, David Hall, Scott C. Kogan, Julia Meyer, Steven D. Rhodes, Xiaoling Xuei, Kevin Shannon, Mignon L. Loh, Elizabeth Fox, Brenda J. Weigel
Journal: Blood
Blood (2023) 142 (Supplement 1): 74.
https://doi.org/10.1182/blood-2023-173153
Published: 2023
Journal Articles

The in Vitro and In Vivo Effects of DPP-4 Inhibition with Sitagliptin, Alone and in Combination with Bortezomib, on T Cell Activation: Rationale for GvHD Prevention

Shuhong Zhang, Xingkui Xue, Maggie Granatir, George E. Sandusky, Sheng Liu, Jun Wan, Xiaoling Xuei, Yunlong Liu, Anthony L. Sinn, Karen E. Pollok, Sherif S Farag
Journal: Blood
Blood (2022) 140 (Supplement 1): 10204–10205.
https://doi.org/10.1182/blood-2022-163679
Published: 2022
Journal Articles

Oral Anti-CD3 and Bioencapsulated FVIII Therapy Exhibit Distinct Mechanisms That Suppress Inhibitor Formation in Hemophilia a

Moanaro Biswas, Thais Bertolini, Kaman So, Jyoti Rana, Sandeep R.P. Kumar, Sha Cao, Hongyu Gao, Xiaoling Xuei, Henry Daniell, Roland W. Herzog
Journal: Blood
Blood (2022) 140 (Supplement 1): 11273–11274.
https://doi.org/10.1182/blood-2022-169734
Published: 2022